Date: September, 28, 2021	
Your Name: Yu-Long Chen	
Manuscript Title: Study on the mechanism of ErtongKe granules in the treatment of cough using netw	ork
pharmacology and molecular docking technology	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None			
	speakers bureaus, manuscript writing or educational events				
6	Payment for expert	√_None			
	testimony				
_					
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or	√_None			
	pending				
9	Participation on a Data	√None			
9	Safety Monitoring Board or	None			
	Advisory Board				
10	Leadership or fiduciary role	_√_None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	√_None			
12	Receipt of equipment,	√None			
12	materials, drugs, medical	<u> </u>			
	writing, gifts or other				
	services				
13	Other financial or non-	√_None			
	financial interests				
	Please summarize the above conflict of interest in the following box:				
	have declared no conflict of int	C1 C3L.			
L					
Dles	Please place an "V" payt to the following statement to indicate your agreement:				

Date: September, 28, 2021	
Your Name: Wei-Xia Li	
Manuscript Title: <u>Study on the mechanism of ErtongKe granules in the treatment of cough using nety</u>	work
pharmacology and molecular docking technology	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None			
	speakers bureaus, manuscript writing or educational events				
6	Payment for expert	√_None			
	testimony				
_					
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or	√_None			
	pending				
9	Participation on a Data	√None			
9	Safety Monitoring Board or	None			
	Advisory Board				
10	Leadership or fiduciary role	_√_None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	√_None			
12	Receipt of equipment,	√None			
12	materials, drugs, medical	<u> </u>			
	writing, gifts or other				
	services				
13	Other financial or non-	√_None			
	financial interests				
	Please summarize the above conflict of interest in the following box:				
	have declared no conflict of int	C1 C3L.			
L					
Dles	Please place an "V" payt to the following statement to indicate your agreement:				

Date:_	September	·, 28, 2021	
Your N	Name: Hui	i Zhang	
Manu	script Title: <u>St</u>	tudy on the mechanism of ErtongKe granules in the treatment of cough using netwo	ork
pharr	macology and	d molecular docking technology	
- Manus	script number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial None	pranning or the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None			
	speakers bureaus, manuscript writing or educational events				
6	Payment for expert	√_None			
	testimony				
_					
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or	√_None			
	pending				
9	Participation on a Data	√None			
9	Safety Monitoring Board or	None			
	Advisory Board				
10	Leadership or fiduciary role	_√_None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	√_None			
12	Receipt of equipment,	√None			
12	materials, drugs, medical	<u> </u>			
	writing, gifts or other				
	services				
13	Other financial or non-	√_None			
	financial interests				
	Please summarize the above conflict of interest in the following box:				
	have declared no conflict of int	C1 C3L.			
L					
Dles	Please place an "V" payt to the following statement to indicate your agreement:				

Date:_	Septem	mber, 28, 2021	_
Your N	lame:	Xiao-Yan Wang	
Manus	cript Title	e: Study on the mechanism of ErtongKe granules in the treatment of cough us	sing network
pharn	nacology	v and molecular docking technology	
- Manus	cript num	mber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None			
	speakers bureaus, manuscript writing or educational events				
6	Payment for expert	√_None			
	testimony				
_					
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or	√_None			
	pending				
9	Participation on a Data	√None			
9	Safety Monitoring Board or	None			
	Advisory Board				
10	Leadership or fiduciary role	_√_None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	√_None			
12	Receipt of equipment,	√None			
12	materials, drugs, medical	<u> </u>			
	writing, gifts or other				
	services				
13	Other financial or non-	√_None			
	financial interests				
	Please summarize the above conflict of interest in the following box:				
	have declared no conflict of int	C1 C3L.			
L					
Dles	Please place an "V" payt to the following statement to indicate your agreement:				

Date:_	Septen	nber, 28, 2021	
Your N	Name:	Shu-Qi Zhang	
Manu	script Title	e: Study on the mechanism of ErtongKe granules in the treatment of cough using netwo	rk
phari	nacology	and molecular docking technology	
Manu	script nun	nber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	√_None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
9	Participation on a Data	√None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√_None	
12	Receipt of equipment,	√None	
12	materials, drugs, medical	<u> </u>	
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		
	se summarize the above co		owing box:
	nave deciared no commict of mil	C1 C3L.	
L			
Dles	uso place an "V" poyt to the	following statement to inc	licate vour agroement:

Date:_	Septer	mber, 28, 2021	
Your N	Name:	Ming-Liang Zhang	
Manu	script Title	e: Study on the mechanism of ErtongKe granules in the treatment of cough using netwo	rk
phari	nacology	v and molecular docking technology	
Manu	script nur	mber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	√_None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
9	Participation on a Data	√None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√_None	
12	Receipt of equipment,	√None	
12	materials, drugs, medical	<u> </u>	
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		
	se summarize the above co		owing box:
	nave deciared no commict of mil	C1 C3L.	
L			
Dles	uso place an "V" poyt to the	following statement to inc	licate vour agroement:

Date	e: September, 28, 2021		
You	Name: Jun Han		
Man	uscript Title: Study on the	e mechanism of Ertongk	Ke granules in the treatment of cough using network
pha	rmacology and molecula	r docking technology	
Man	uscript number (if known):		
relat part to tr relat	eed to the content of your name ies whose interests may be ansparency and does not not not interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of the manuscript in doubt about whether to list a so.
to th med In ito	ne epidemiology of hyperte ication, even if that medica	nsion, you should declare a stion is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.  I in this manuscript without time limit. For all other items
		T	·
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	I planning of the work
1	All support for the present	√ None	
_	manuscript (e.g., funding,	None	
ŀ	provision of study materials,		
	medical writing, article		
ŀ	processing charges, etc.)		
Ì	No time limit for this item.		
Î			
İ			
		Time frame: past	36 months
2	Grants or contracts from	√_None	
j	any entity (if not indicated		
أ	in item #1 above).		
3	Royalties or licenses	√_None	
İ			
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
-	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	√_None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√_None	
	·		
10			
12	Receipt of equipment, materials, drugs, medical	√_None	
	writing, gifts or other services		
13	Other financial or non- financial interests	Yangtze River Pharmaceutical Group	
-			
Plea	se summarize the above co	onflict of interest in the fo	llowing box:
D	r. Jun Han is from Yangtze Rive	er Pharmaceutical Group.	
	C	·	
D!	ise place an "X" next to the	fallanda akatawa ta	di ada arang arang arang arang arang arang arang arang arang arang arang arang arang arang arang arang arang ar
PIES	ise place an "X" next to the	TOUOWING STATEMENT TO IN	dicate volir agreement:

form.

Date: September, 28, 2021
Your Name: Kun Li
Manuscript Title: <u>Study on the mechanism of ErtongKe granules in the treatment of cough using network</u>
pharmacology and molecular docking technology
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	√_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	√_None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
9	Participation on a Data	√None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√_None	
12	Receipt of equipment,	√None	
12	materials, drugs, medical	<u> </u>	
	writing, gifts or other		
	services		
13	Other financial or non-	√_None	
	financial interests		
	se summarize the above co		owing box:
	nave deciared no commict of mil	C1 C3L.	
L			
Dles	uso place an "V" poyt to the	following statement to inc	licate vour agroement:

Date:_	Septe	mber, 28, 2	2021	
Your N	Name:	Ke-Ran F	Feng	
Manus	script Titl	e: Study o	on the mechanism of ErtongKe granules in the treatment of cough using netwo	vork
pharr	nacology	v and mol	olecular docking technology	
- Manus	script nui	mber (if kn	nown):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None		
	speakers bureaus, manuscript writing or educational events			
6	Payment for expert	√_None		
	testimony			
_				
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	√None		
<u>.</u>	pending			
9	Participation on a Data	√None		
9	Safety Monitoring Board or	None		
	Advisory Board			
10	Leadership or fiduciary role	_√_None		
	in other board, society,			
İ	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	√_None		
i i				
12	Receipt of equipment,	_√_None		
12	materials, drugs, medical	<u> </u>		
	writing, gifts or other			
	services			
13	Other financial or non-	√_None		
	financial interests			
	Please summarize the above conflict of interest in the following box:			
	I have declared no conflict of interest.			
Dlaa	Please place an "Y" payt to the following statement to indicate your agreement:			

Date: September, 28, 2021	
Your Name: Xiao-Fei Chen	
Manuscript Title: <u>Study on the mechanism of ErtongKe granules in the treatment of cough using net</u>	work
pharmacology and molecular docking technology	
Manuscript number (if known):	_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
Time frame: past 36 months			36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None		
	speakers bureaus, manuscript writing or educational events			
6	Payment for expert	√_None		
	testimony			
_				
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	√None		
<u>.</u>	pending			
9	Participation on a Data	√None		
9	Safety Monitoring Board or	None		
	Advisory Board			
10	Leadership or fiduciary role	_√_None		
	in other board, society,			
İ	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	√_None		
i i				
12	Receipt of equipment,	_√_None		
12	materials, drugs, medical	<u> </u>		
	writing, gifts or other			
	services			
13	Other financial or non-	√_None		
	financial interests			
	Please summarize the above conflict of interest in the following box:			
	I have declared no conflict of interest.			
Dlaa	Please place an "Y" payt to the following statement to indicate your agreement:			

Date:	September, 28, 2021	
Your Na	me: Jin-Fa Tang	
Manusci	ript Title: Study on the mechanism of ErtongKe granules in the treatment of cough using networ	·k
pharma	acology and molecular docking technology	
Manusci	ript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	None		
	speakers bureaus, manuscript writing or educational events			
6	Payment for expert	√_None		
	testimony			
_				
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	√None		
<u>.</u>	pending			
9	Participation on a Data	√None		
9	Safety Monitoring Board or	None		
	Advisory Board			
10	Leadership or fiduciary role	_√_None		
	in other board, society,			
İ	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	√_None		
i i				
12	Receipt of equipment,	_√_None		
12	materials, drugs, medical	<u> </u>		
	writing, gifts or other			
	services			
13	Other financial or non-	√_None		
	financial interests			
	Please summarize the above conflict of interest in the following box:			
	I have declared no conflict of interest.			
Dlaa	Please place an "Y" payt to the following statement to indicate your agreement:			